Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity. / Stensman, Lars M; Kjeldsen, Eigil; Nersting, Jacob; Schmiegelow, K.; Hasle, Henrik.

I: Journal of Pediatric Hematology/Oncology, Bind 37, Nr. 4, 2015, s. e242–e244.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Stensman, LM, Kjeldsen, E, Nersting, J, Schmiegelow, K & Hasle, H 2015, 'Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity', Journal of Pediatric Hematology/Oncology, bind 37, nr. 4, s. e242–e244. https://doi.org/10.1097/MPH.0000000000000211

APA

Stensman, L. M., Kjeldsen, E., Nersting, J., Schmiegelow, K., & Hasle, H. (2015). Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity. Journal of Pediatric Hematology/Oncology, 37(4), e242–e244. https://doi.org/10.1097/MPH.0000000000000211

Vancouver

Stensman LM, Kjeldsen E, Nersting J, Schmiegelow K, Hasle H. Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity. Journal of Pediatric Hematology/Oncology. 2015;37(4):e242–e244. https://doi.org/10.1097/MPH.0000000000000211

Author

Stensman, Lars M ; Kjeldsen, Eigil ; Nersting, Jacob ; Schmiegelow, K. ; Hasle, Henrik. / Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity. I: Journal of Pediatric Hematology/Oncology. 2015 ; Bind 37, Nr. 4. s. e242–e244.

Bibtex

@article{790e9b6090874348b5a7cf3d6a4ebe17,
title = "Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity",
abstract = "INTRODUCTION: We describe a patient diagnosed with acute myeloid leukemia (AML) and low activity of thiopurine methyltransferase (TPMT) who developed secondary myelodysplastic syndrome after treatment.OBSERVATION: A 10-year-old boy presented with AML-M2 with t(8;21)(q22;q22) and genotyping revealing 3*B TPMT heterozygosity. The patient was treated according to the NOPHO-AML 2004 protocol. Two years after the treatment, the patient presented with neutropenia and thrombocytopenia. Bone marrow, including fluorescent in situ hybridization and retrospective aCGH analysis, verified therapy-related myelodysplastic syndrome with ring chromosome 6.DISCUSSION: The clinical course of this patient raises the possibility that low-activity TPMT genotypes may influence 6TG toxicity in patients with AML and lead to an increased risk of developing secondary malignant neoplasms.",
author = "Stensman, {Lars M} and Eigil Kjeldsen and Jacob Nersting and K. Schmiegelow and Henrik Hasle",
year = "2015",
doi = "10.1097/MPH.0000000000000211",
language = "English",
volume = "37",
pages = "e242–e244",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams & Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity

AU - Stensman, Lars M

AU - Kjeldsen, Eigil

AU - Nersting, Jacob

AU - Schmiegelow, K.

AU - Hasle, Henrik

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: We describe a patient diagnosed with acute myeloid leukemia (AML) and low activity of thiopurine methyltransferase (TPMT) who developed secondary myelodysplastic syndrome after treatment.OBSERVATION: A 10-year-old boy presented with AML-M2 with t(8;21)(q22;q22) and genotyping revealing 3*B TPMT heterozygosity. The patient was treated according to the NOPHO-AML 2004 protocol. Two years after the treatment, the patient presented with neutropenia and thrombocytopenia. Bone marrow, including fluorescent in situ hybridization and retrospective aCGH analysis, verified therapy-related myelodysplastic syndrome with ring chromosome 6.DISCUSSION: The clinical course of this patient raises the possibility that low-activity TPMT genotypes may influence 6TG toxicity in patients with AML and lead to an increased risk of developing secondary malignant neoplasms.

AB - INTRODUCTION: We describe a patient diagnosed with acute myeloid leukemia (AML) and low activity of thiopurine methyltransferase (TPMT) who developed secondary myelodysplastic syndrome after treatment.OBSERVATION: A 10-year-old boy presented with AML-M2 with t(8;21)(q22;q22) and genotyping revealing 3*B TPMT heterozygosity. The patient was treated according to the NOPHO-AML 2004 protocol. Two years after the treatment, the patient presented with neutropenia and thrombocytopenia. Bone marrow, including fluorescent in situ hybridization and retrospective aCGH analysis, verified therapy-related myelodysplastic syndrome with ring chromosome 6.DISCUSSION: The clinical course of this patient raises the possibility that low-activity TPMT genotypes may influence 6TG toxicity in patients with AML and lead to an increased risk of developing secondary malignant neoplasms.

U2 - 10.1097/MPH.0000000000000211

DO - 10.1097/MPH.0000000000000211

M3 - Journal article

C2 - 25000470

VL - 37

SP - e242–e244

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -

ID: 138138946